Establishment Labs (NASDAQ:ESTA) Shares Down 3.9% – What’s Next?

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s stock price was down 3.9% during trading on Thursday . The stock traded as low as $34.52 and last traded at $34.83. Approximately 89,377 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 855,608 shares. The stock had previously closed at $36.23.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ESTA. BTIG Research raised their price target on Establishment Labs from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Citigroup increased their price objective on shares of Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. Finally, Stephens raised Establishment Labs to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $60.60.

Establishment Labs Stock Performance

The company’s fifty day simple moving average is $42.55 and its 200 day simple moving average is $43.25. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The stock has a market capitalization of $953.29 million, a price-to-earnings ratio of -13.20 and a beta of 1.15.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.02. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The firm had revenue of $40.23 million for the quarter, compared to analysts’ expectations of $40.60 million. During the same period in the prior year, the firm earned ($1.12) EPS. On average, equities research analysts expect that Establishment Labs Holdings Inc. will post -2.42 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Healthcare of Ontario Pension Plan Trust Fund grew its position in Establishment Labs by 1.8% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 35,236 shares of the company’s stock worth $1,525,000 after buying an additional 632 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Establishment Labs during the 4th quarter worth $36,000. Verition Fund Management LLC raised its stake in Establishment Labs by 22.8% in the third quarter. Verition Fund Management LLC now owns 9,400 shares of the company’s stock valued at $407,000 after purchasing an additional 1,746 shares in the last quarter. HighTower Advisors LLC raised its stake in Establishment Labs by 32.5% in the third quarter. HighTower Advisors LLC now owns 10,311 shares of the company’s stock valued at $446,000 after purchasing an additional 2,529 shares in the last quarter. Finally, SkyView Investment Advisors LLC lifted its position in Establishment Labs by 30.5% during the third quarter. SkyView Investment Advisors LLC now owns 12,000 shares of the company’s stock worth $519,000 after purchasing an additional 2,805 shares during the period. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.